CCDC62

Across TCGA pan-cancer cohorts, CCDC62 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC62 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CCDC62 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC62 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, STAD, and HNSC are the cancer types where CCDC62 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.618	.005	30	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
HNSC	OS	Median	All	0.191	0.751	.003	12	view →
SKCM	DFS	Median	All	0.932	0.727	.008	12	view →
COAD	DFS	Median	All	0.197	0.526	.018	5	view →
LUSC	OS	Median	III,IV	0.268	0.669	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC62–UCEC (DFS)

Open the UCEC breakdown →